Form 8-K - Current report:
SEC Accession No. 0001564590-22-001203
Filing Date
2022-01-13
Accepted
2022-01-13 16:00:29
Documents
13
Period of Report
2022-01-11
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K FOR BVF COMMON SHARE EXCHANGE AGREEMENT eldn-8k_20220111.htm   iXBRL 8-K 39847
2 EX-10.1 eldn-ex101_9.htm EX-10.1 52117
  Complete submission text file 0001564590-22-001203.txt   228003

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA eldn-20220111.xsd EX-101.SCH 5685
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE eldn-20220111_lab.xml EX-101.LAB 19431
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eldn-20220111_pre.xml EX-101.PRE 11576
7 EXTRACTED XBRL INSTANCE DOCUMENT eldn-8k_20220111_htm.xml XML 3547
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36620 | Film No.: 22529052
SIC: 2834 Pharmaceutical Preparations